ArticleClinical pharmacology and therapeutics2026

Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan's National Claims Database.

Hotaka Maruyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.